Stay updated on SAGE-718 Effects in AD: Mild Cognitive Impairment Clinical Trial

Sign up to get notified when there's something new on the SAGE-718 Effects in AD: Mild Cognitive Impairment Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the SAGE-718 Effects in AD: Mild Cognitive Impairment Clinical Trial page

  1. Check
    2 days ago
    No Change Detected
  2. Check
    9 days ago
    No Change Detected
  3. Check
    16 days ago
    Change Detected
    Summary
    Updated the page to v3.2.0 with a prominent notice about potential data/tansaction delays due to funding gaps and where to check operating status; previous v3.1.0 reference removed.
    Difference
    3%
    Check dated 2025-10-05T10:12:33.000Z thumbnail image
  4. Check
    23 days ago
    Change Detected
    Summary
    Updated the page revision from v3.0.2 to v3.1.0, indicating a new software release or document update. No changes to core content, pricing, or stock are evident.
    Difference
    0.1%
    Check dated 2025-09-28T03:18:25.000Z thumbnail image
  5. Check
    30 days ago
    Change Detected
    Summary
    Rebranding from Sage Therapeutics to Supernus Pharmaceuticals, Inc., with newer update/posting dates to reflect current information.
    Difference
    1%
    Check dated 2025-09-20T22:08:54.000Z thumbnail image
  6. Check
    38 days ago
    Change Detected
    Summary
    The page now shows Revision: v3.0.2, replacing v3.0.1, and the Back to Top element has been removed; this signals a simple release update with minor UI change.
    Difference
    0.2%
    Check dated 2025-09-13T17:39:39.000Z thumbnail image
  7. Check
    45 days ago
    Change Detected
    Summary
    The web page has been updated from version 3.0.0 to 3.0.1, indicating a revision in the content. There are no significant changes to core content, names, pricing, or availability.
    Difference
    0.2%
    Check dated 2025-09-06T15:21:47.000Z thumbnail image
  8. Check
    52 days ago
    Change Detected
    Summary
    The web page has undergone significant changes, including the addition of a facility name and location details, specifically Bayamón, Puerto Rico, while also removing various references to locations and resources related to Alzheimer's disease.
    Difference
    3%
    Check dated 2025-08-30T11:57:20.000Z thumbnail image

Stay in the know with updates to SAGE-718 Effects in AD: Mild Cognitive Impairment Clinical Trial

Enter your email address, and we'll notify you when there's something new on the SAGE-718 Effects in AD: Mild Cognitive Impairment Clinical Trial page.